Outcomes of ritonavir-boosted protease inhibitor versus non-nucleoside reverse transcriptase regimens in a clinical practice cohort

Journal of Antivirals and Antiretrovirals

Volumn 2, Issue 1, 2010, Pages 13-19

  Moore, Richard D ^a   Kumar, Ritesh ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adherence; Adverse events; Boosted regimens; Nonnucleoside reverse transcriptase inhibitors; Quality of life; Resistance

Indexed keywords

AMPRENAVIR; ATAZANAVIR; EFAVIRENZ; FOSAMPRENAVIR; INDINAVIR; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; QUALITY OF LIFE; SELF REPORT; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77954669940     PISSN: None     EISSN: 19485964     Source Type: Journal    
DOI: 10.4172/jaa.1000016     Document Type: Article

References (34)

1. Aberg JA (2009) Cardiovascular complications in HIV management: Past, present, and future. J Acquir Immune Defic Syndr 50: 54-64.
2. Abrescia N, D'Abbraccio M, Figoni M, Busto A, Maddaloni A, et al. (2005) Hepatotoxicity of antiretroviral drugs. Curr Pharm Des 11: 3697-3710.
3. Ammassari A, Murri R, Pezzotti, Trotta MP, Ravasio L, et al. (2001) AdlCONA Study Group. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 28: 445-449.
4. Capetti AF, Piconi S, Landonio S, Rizzardini G, Perno CF (2009) Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? J Acquir Immune Defic Syndr 50: 233-234.
5. Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351: 1881-1883.
6. Carrieri MP, Villes V, Raffi F, Protopopescu C, Preau M, et al. (2007) APROCO-COPILOTE ANRS CO-08 Study Group. Self-reported sideeffects of anti-retroviral treatment among IDUs: a 7-year longitudinal study. Int J Drug Policy 18: 288-295.
7. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, et al. (2007) Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369: 1169-1178.
8. Crane HM, Van Rompaey SE, Kitahata MM (2006) Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 20: 1019-1026.
9. Fellay J, Boubaker K, Ledergerber, Bernasconi E., Furrer H, et al. (2001) Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358: 1322-1327.
10. Flint OP, Noor MA, Hruz PW, Hylemon PB, Yarasheski K, et al. (2009) The role of protease inhibitors in the pathogenesis of HIVassociated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol 37: 65-77.
11. Gross R, Yip B, Lo Re V 3rd, Wood E, Alexander CS, et al. (2006) A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 194: 1108-1114.
12. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA Panel. JAMA 300: 555-570.
13. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, et al. (2006) Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomized open-label trials. Lancet 368: 466-475.
14. Hirsch MS, Gunthard HF, Shapiro JM, Brun-Vézinet F, Clotet B, et al. (2008) Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS society-USA panel. Clin Infect Dis 47: 266-285.
15. Kontorinis N, Dieterich DT (2003) Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 23: 173-182.
16. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, et al. (2007) Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1- infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370: 39-48.
17. Lennox J, DeJesus E, Lazzarin A, Pollard R, Madruga J, et al. (2009) Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet. 374: 796-806.
18. Lichterfeld M, Wöhrmann A, Schmeisser N, Fätkenheuer G, Salzberger B, et al. (2003) Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy. Eur J Med Res 8: 56-60.
19. Lundgren J, Reiss P, Worm S, Weber R, El-Sadr W, et al. (2009) Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: the D:A:D study. Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, Canada. Abstract 44LB.
20. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, et al. (2007) Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370: 29-38.
21. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, et al. (2007) Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as a part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46: 125-133.
22. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D (2003) Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17: 2479-2486.
23. Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, et al. (2004) Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis 190: 1947-1956.
24. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine or efavirenz-based antiretroviral therapy. Clin Infect Dis 38: 1311-1316.
25. Powderly WG (2002) Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 29: S28-S40.
26. Rivero A, Mira JA, Pineda JA (2007) Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 59: 342-346.
27. Sax PE, Kumar P (2004) Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 37: 1111-1124.
28. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF (2008) Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 105: 4832-4837.
29. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 37: 1112-1118.
30. Shikuma CM, Yang Y, Glesby MJ, Meyer WA 3rd, Tashima KT, et al. (2007) Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 44: 540-550.
31. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, et al. (2008) BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359: 339-354.
32. Trotta MP, Ammassari A, Melzi S, Zaccarelli M, Ladisa N, et al. (2002) reatment-related factors and highly active antiretroviral therapy adherence. J cquir Immune Defic Syndr 31: S128-S131.
33. US Department of Health and Human Services (DHHS) (2009) Guidelines for he use of antiretroviral agents in HIV-1-infected adults and adolescents.
34. Wood E, Hogg R, Yip B, Moore D, Harrigan P, et al. (2007) Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme. HIV Med 8: 80-85.